ME02644B - Novi preparati alfentanila za tretman akutnog bola - Google Patents
Novi preparati alfentanila za tretman akutnog bolaInfo
- Publication number
- ME02644B ME02644B MEP-2017-9A MEP20179A ME02644B ME 02644 B ME02644 B ME 02644B ME P20179 A MEP20179 A ME P20179A ME 02644 B ME02644 B ME 02644B
- Authority
- ME
- Montenegro
- Prior art keywords
- preparation
- alfentanil
- carrier particles
- treatment
- pain
- Prior art date
Links
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 title claims 7
- 229960001391 alfentanil Drugs 0.000 title claims 7
- 208000002193 Pain Diseases 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 4
- 208000005298 acute pain Diseases 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims 18
- 238000000034 method Methods 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000011859 microparticle Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 238000007580 dry-mixing Methods 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- 229940098466 sublingual tablet Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims 1
- 235000019801 trisodium phosphate Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (17)
1. Farmaceutski preparat pogodan za sublingvalnu isporuku, kao i za brzo oslobađanje alfentanila i/ili za brzu resorpciju alfentanila putem oralne sluzokože, koji sadrži smešu sastavljenu od:(a) mikročestica alfentanila, ili njegove farmaceutski prihvatljive soli, naznačenih time, što se mikročestice nalaze na površinama većih čestica nosača;(b) slabe baze; i(c) jedinjenja koje predstavlja slabu kiselinu, naznačenog time, što je kiselina prisutna u bliskoj smeši sa mikročesticama alfentanila ili njegove soli i što je kiselina prisutna bilo:(1) unutar čestica nosača, odnosno tako da navedene čestice nosača sadrže kompozit: (i) navedenog materijala kiseline; i (ii) drugih materijala koji se upotrebljavaju za pripremu čestica nosača; ili (2) na površinama čestica nosača.
2. Preparat prema patentnom zahtjevu 1, naznačen time što kiselina označava limunsku kiselinu.
3. Preparat prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što slaba baza sadrži fosfat.
4. Preparat prema patentnom zahtjevu 3, naznačen time što slaba baza označava trinatrijum fosfat.
5. Preparat prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što čestice nosača sadrže manitol.
6. Farmaceutski preparat prema bilo kojem od prethodnih patentnih zahtjeva koji dalje sadrži sredstvo za razlaganje (dezintegrans).
7. Preparat prema patentnom zahtjevu 6, naznačen time što sredstvo za razlaganje označava superdezintegrans izabran iz grupe koju čine kroskarmeloza-natrijum, natrijum skrob glikolat, umreženi polivinilpirolidon ili njihova smeša.
8. Preparat prema patentnom zahtjevu 1, naznačen time, što je baza rastvorljiva u vodi.
9. Preparat prema bilo kom od prethodnih patentnih zahtjeva, naznačen time što je preparat u obliku tablete koja je pogodna za sublingvalnu primenu.
10. Postupak pripreme preparata definisanog bilo kojim od patentnih zahtjeva od 1 do 9, koji sadrži čestice nosača izmešane postupkom suvog mešanja sa alfentanilom ili njegovom solju.
11. Postupak pripreme sublingvalne tablete definisan u patentnom zahtjevu 9, naznačen time, što postupak obuhvata direktnu kompresiju ili sabijanje preparata definisanog bilo kojim od patetnih zahtjeva od 1 do 8.
12. Preparat prema bilo kojem od patentnih zahtjeva od 1 do 9 za upotrebu u postupku tretmana bola.
13. Preparat za upotrebu prema patentnom zahtjevu 12, naznačen time što bol označava bol umjerenog do jakog intenziteta.
14. Preparat za upotrebu prema patentnom zahtjevu 13, naznačen time, što tretman označava kratkotrajan tretman.
15. Preparat za upotrebu pprema patentnom zahtjevu 13 ili patentnim zahtjevom 14, naznačen time što bol prati dijagnostičke, hirurške ili procedure njege pacijenata.
16. Preparat za upotrebu pema patentnom zahtjevu 15, naznačen time što se preparat primjenjuje u vremenskom periodu koji nije veći od oko 20 minuta prije procedure.
17. Preparat za upotrebu definisanu bilo kojim od patentnih zahtjeva od 12 do 16, naznačen time što postupak tretmana bola obuhvata sublingvalnu primenu humanom pacijentu kome je tretman potreban, farmaceutskog preparata koji sadrži između oko 30 µg i oko 3,000 µg alfentanila ili njegove farmaceutski prihvatljive soli, i što navedena primjena dovodi do krive zavisnosti koncentracije u plazmi i vremena nakon navedene primjene koju karakterišu: (I) tmax (vrijeme potrebno za postizanje maksimalne koncentracije u plazmi) između oko 10 i oko 25 minuta nakon navedene primjene; i/ili (II) tlast (vrijeme poslednje mjerljive koncentracije u plazmi) koji nije veće od oko 300 minuta nakon navedene primjene; i opciono, (III) Cmax (maksimalna koncentracija u plazmi) između oko 10 i oko 100 ng po ml plazme.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1207701.2A GB201207701D0 (en) | 2012-05-02 | 2012-05-02 | New pharmaceutical composition |
| GBGB1221130.6A GB201221130D0 (en) | 2012-11-23 | 2012-11-23 | New pharmaceutical composition |
| PCT/GB2013/051131 WO2013164620A1 (en) | 2012-05-02 | 2013-05-01 | New alfentanil composition for the treatment of acute pain |
| EP13727314.0A EP2849730B1 (en) | 2012-05-02 | 2013-05-01 | New alfentanil composition for the treatment of acute pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02644B true ME02644B (me) | 2017-06-20 |
Family
ID=48577134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-9A ME02644B (me) | 2012-05-02 | 2013-05-01 | Novi preparati alfentanila za tretman akutnog bola |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US8815911B2 (me) |
| EP (2) | EP2849730B1 (me) |
| JP (1) | JP6275696B2 (me) |
| KR (1) | KR20150005695A (me) |
| CN (1) | CN104427978B (me) |
| AU (1) | AU2013255640B2 (me) |
| BR (1) | BR112014027213A8 (me) |
| CA (1) | CA2871805A1 (me) |
| CL (1) | CL2014002979A1 (me) |
| CO (1) | CO7170181A2 (me) |
| CY (2) | CY1118570T1 (me) |
| DK (2) | DK3150199T3 (me) |
| EA (1) | EA028110B1 (me) |
| ES (2) | ES2694644T3 (me) |
| HR (2) | HRP20161634T1 (me) |
| HU (1) | HUE031792T2 (me) |
| IL (1) | IL235272B (me) |
| IN (1) | IN2014MN02156A (me) |
| LT (2) | LT2849730T (me) |
| ME (1) | ME02644B (me) |
| MX (1) | MX360665B (me) |
| NZ (1) | NZ701428A (me) |
| PE (1) | PE20142444A1 (me) |
| PH (1) | PH12014502407B1 (me) |
| PL (2) | PL2849730T3 (me) |
| PT (2) | PT3150199T (me) |
| RS (2) | RS57951B1 (me) |
| SG (1) | SG11201407081PA (me) |
| SI (2) | SI2849730T1 (me) |
| SM (3) | SMT201800585T1 (me) |
| TR (1) | TR201815935T4 (me) |
| WO (1) | WO2013164620A1 (me) |
| ZA (1) | ZA201407559B (me) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY185284A (en) | 2011-09-19 | 2021-04-30 | Orexo Ab | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
| KR20150005695A (ko) * | 2012-05-02 | 2015-01-14 | 오렉쏘 에이비 | 급성 통증을 치료하기 위한 신규한 알펜타닐 조성물 |
| US10766925B2 (en) * | 2016-04-11 | 2020-09-08 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Opioid receptor modulators |
| JP7023054B2 (ja) * | 2017-04-05 | 2022-02-21 | 東和薬品株式会社 | レベチラセタム含有医薬組成物及びその製造方法 |
| CN115047109B (zh) * | 2022-06-17 | 2024-05-31 | 三明海关综合技术服务中心 | 一种检测食品中芬太尼类新精神活性物质的方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| DE19749724A1 (de) | 1997-11-11 | 1999-06-10 | Gruenenthal Gmbh | Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln |
| SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
| SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| GB9904911D0 (en) | 1999-03-03 | 1999-04-28 | Scherer Ltd R P | Pharmaceutical compositions |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US20020160043A1 (en) | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
| JP4850346B2 (ja) | 2001-03-15 | 2012-01-11 | 救急薬品工業株式会社 | 粘膜貼付剤 |
| US20030068356A1 (en) | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| JP2006516616A (ja) | 2003-01-31 | 2006-07-06 | オレクソ・アクチエボラゲット | 即効薬剤組成物 |
| KR101170844B1 (ko) | 2003-02-24 | 2012-08-02 | 파마슈티칼 프로덕션스, 인크. | 경점막 약물 전달 시스템 |
| US20050042281A1 (en) | 2003-08-21 | 2005-02-24 | Singh Nikhilesh N. | Compositions for delivering therapeutic agents across the oral mucosa |
| AU2004311879B2 (en) | 2003-12-31 | 2010-08-05 | Phoenix Labs Unlimited Company | Effervescent oral opiate dosage form |
| US7858121B2 (en) * | 2003-12-31 | 2010-12-28 | Cima Labs, Inc. | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
| CA2548915C (en) | 2003-12-31 | 2012-10-16 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| US20070036853A1 (en) | 2003-12-31 | 2007-02-15 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| FR2883179B1 (fr) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
| CA2599386A1 (en) | 2005-03-28 | 2006-10-05 | Orexo Ab | New pharmaceutical compositions useful in the treatment of pain |
| US20060281775A1 (en) * | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
| US20070104763A1 (en) * | 2005-11-10 | 2007-05-10 | Navinta Llc | Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8535714B2 (en) * | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US20100233257A1 (en) | 2006-06-09 | 2010-09-16 | Ethypharm | Low dose sublingual tablets of opioid analgesics and preparation process |
| US20070286900A1 (en) | 2006-06-09 | 2007-12-13 | Catherine Herry | Low dose tablets of opioid analgesics and preparation process |
| SI2054031T1 (sl) * | 2006-07-21 | 2016-09-30 | Biodelivery Sciences International, Inc. | Transmukozne naprave za administracijo z izboljšanim vnosom |
| PL2101740T3 (pl) * | 2006-12-04 | 2014-04-30 | Orexo Ab | Nowa, niepodatna na nadużycie kompozycja farmaceutyczna zawierająca opioidy |
| EP1964564A1 (en) | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
| ES2534433T3 (es) | 2007-08-07 | 2015-04-22 | Acelrx Pharmaceuticals, Inc. | Composiciones que comprenden sufentanilo y triazolam para sedación y analgesia operatorias utilizando formas farmacéuticas transmucosas orales |
| US20090263476A1 (en) * | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
| US8343978B2 (en) | 2008-08-04 | 2013-01-01 | Adds Pharmaceuticals Llc | Fast onset orodispersable tablets |
| US20100056574A1 (en) | 2008-09-04 | 2010-03-04 | Mallinckrodt Inc. | Crystalline Forms of Sufentanil |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| JP2012526840A (ja) | 2009-05-13 | 2012-11-01 | プロテイン デリヴァリー ソリューションズ エルエルシー | 膜貫通送達のための製剤系 |
| WO2010141505A1 (en) | 2009-06-01 | 2010-12-09 | Protect Pharmaceutical Corporation | Abuse-resistant delivery systems |
| JP2009280611A (ja) * | 2009-08-26 | 2009-12-03 | Kyukyu Yakuhin Kogyo Kk | 口腔内粘膜フィルム剤 |
| US20110091544A1 (en) | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
| US20110262442A1 (en) | 2009-11-06 | 2011-10-27 | Adenios, Inc. | Compositions for treating cns disorders |
| US20110150989A1 (en) | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
| KR20150005695A (ko) * | 2012-05-02 | 2015-01-14 | 오렉쏘 에이비 | 급성 통증을 치료하기 위한 신규한 알펜타닐 조성물 |
-
2013
- 2013-05-01 KR KR1020147033700A patent/KR20150005695A/ko not_active Ceased
- 2013-05-01 CN CN201380022630.2A patent/CN104427978B/zh not_active Expired - Fee Related
- 2013-05-01 JP JP2015509496A patent/JP6275696B2/ja not_active Expired - Fee Related
- 2013-05-01 RS RS20181295A patent/RS57951B1/sr unknown
- 2013-05-01 US US13/874,762 patent/US8815911B2/en not_active Expired - Fee Related
- 2013-05-01 PL PL13727314T patent/PL2849730T3/pl unknown
- 2013-05-01 WO PCT/GB2013/051131 patent/WO2013164620A1/en not_active Ceased
- 2013-05-01 RS RS20161161A patent/RS55489B1/sr unknown
- 2013-05-01 EP EP13727314.0A patent/EP2849730B1/en active Active
- 2013-05-01 SM SM20180585T patent/SMT201800585T1/it unknown
- 2013-05-01 ME MEP-2017-9A patent/ME02644B/me unknown
- 2013-05-01 SI SI201330490A patent/SI2849730T1/sl unknown
- 2013-05-01 PT PT16197166T patent/PT3150199T/pt unknown
- 2013-05-01 LT LTEP13727314.0T patent/LT2849730T/lt unknown
- 2013-05-01 HU HUE13727314A patent/HUE031792T2/en unknown
- 2013-05-01 SI SI201331238T patent/SI3150199T1/sl unknown
- 2013-05-01 EA EA201401200A patent/EA028110B1/ru not_active IP Right Cessation
- 2013-05-01 DK DK16197166.8T patent/DK3150199T3/en active
- 2013-05-01 DK DK13727314.0T patent/DK2849730T3/en active
- 2013-05-01 HR HRP20161634TT patent/HRP20161634T1/hr unknown
- 2013-05-01 PE PE2014001937A patent/PE20142444A1/es not_active Application Discontinuation
- 2013-05-01 MX MX2014013176A patent/MX360665B/es active IP Right Grant
- 2013-05-01 LT LTEP16197166.8T patent/LT3150199T/lt unknown
- 2013-05-01 ES ES16197166.8T patent/ES2694644T3/es active Active
- 2013-05-01 PL PL16197166T patent/PL3150199T3/pl unknown
- 2013-05-01 IN IN2156MUN2014 patent/IN2014MN02156A/en unknown
- 2013-05-01 PT PT137273140T patent/PT2849730T/pt unknown
- 2013-05-01 BR BR112014027213A patent/BR112014027213A8/pt not_active Application Discontinuation
- 2013-05-01 SG SG11201407081PA patent/SG11201407081PA/en unknown
- 2013-05-01 NZ NZ701428A patent/NZ701428A/en not_active IP Right Cessation
- 2013-05-01 EP EP16197166.8A patent/EP3150199B1/en active Active
- 2013-05-01 CA CA2871805A patent/CA2871805A1/en not_active Abandoned
- 2013-05-01 SM SM20170086T patent/SMT201700086T1/it unknown
- 2013-05-01 TR TR2018/15935T patent/TR201815935T4/tr unknown
- 2013-05-01 ES ES13727314.0T patent/ES2614757T3/es active Active
- 2013-05-01 AU AU2013255640A patent/AU2013255640B2/en not_active Ceased
-
2014
- 2014-07-15 US US14/331,507 patent/US9345698B2/en not_active Expired - Fee Related
- 2014-10-17 ZA ZA2014/07559A patent/ZA201407559B/en unknown
- 2014-10-22 IL IL235272A patent/IL235272B/en not_active IP Right Cessation
- 2014-10-27 PH PH12014502407A patent/PH12014502407B1/en unknown
- 2014-10-29 CO CO14239767A patent/CO7170181A2/es not_active Application Discontinuation
- 2014-11-03 CL CL2014002979A patent/CL2014002979A1/es unknown
-
2016
- 2016-04-26 US US15/138,570 patent/US9782396B2/en not_active Expired - Fee Related
-
2017
- 2017-01-31 CY CY20171100139T patent/CY1118570T1/el unknown
- 2017-02-08 SM SM201700086T patent/SMT201700086B/it unknown
- 2017-09-11 US US15/701,300 patent/US20180214437A1/en not_active Abandoned
-
2018
- 2018-10-25 HR HRP20181761TT patent/HRP20181761T1/hr unknown
- 2018-11-05 CY CY181101154T patent/CY1120820T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cantekin et al. | Evaluation of shear bond strength of two resin-based composites and glass ionomer cement to pure tricalcium silicate-based cement (Biodentine®) | |
| AU2012222825B2 (en) | Chewable vehicle for mouth absorption | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| EP3189854B1 (en) | Vaccine composition for transdermal or transmucosal administration | |
| ME02644B (me) | Novi preparati alfentanila za tretman akutnog bola | |
| JP2014517825A5 (me) | ||
| BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2022009901A (ja) | マグネシウム含有オキシトシン製剤および使用の方法 | |
| CL2009002183A1 (es) | Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica. | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| HRP20161444T1 (hr) | Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| US20230001128A1 (en) | Aerosolization systems, methods, and apparatuses | |
| RU2013148120A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| JP2017519568A5 (me) | ||
| NZ617397A (en) | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units | |
| JP2013520448A5 (me) | ||
| RS58543B2 (sr) | Optimizovana farmaceutska formulacija za lečenje zapaljenskih promena ezofagusa | |
| JP5622775B2 (ja) | 皮膚病の治療用組成物、並びにそれを用いた製剤及びその調製方法 | |
| JP2015515974A5 (me) | ||
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена | |
| JP2025166003A (ja) | 咽頭反射の処置のための組成物および治療 | |
| JP2015512923A5 (me) | ||
| Pinzon et al. | Bond strength of adhesives to dentin contaminated with smoker’s saliva | |
| RU2590978C1 (ru) | Капсулированный препарат для лечения простуды и способ его получения |